$34.04
+1.63 (+5.03%)
Open$31.78
Previous Close$32.41
Day High$35.20
Day Low$31.78
52W High$910.00
52W Low$15.10
Volume—
Avg Volume36.3K
Market Cap33.61M
P/E Ratio—
EPS$-116.84
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+17.9% upside
Current
$34.04
$34.04
Target
$40.14
$40.14
$31.69
$40.14 avg
$63.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 548.9K | 523.5K | 509.5K |
| Net Income | 128.1K | 108.5K | 123.6K |
| Profit Margin | 23.3% | 20.7% | 24.3% |
| EBITDA | 177.1K | 173.7K | 174.5K |
| Free Cash Flow | 145.7K | 139.2K | 108.0K |
| Rev Growth | +23.9% | +19.4% | -4.0% |
| Debt/Equity | 0.65 | 0.64 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |